Jasper Therapeutics

Also Clin1/Clin2 AML/MDS, Clin1/Clin2 Fanconi's anemia, Clin1/Clin2 sickle cell disease; Clin0 chronic granulomatous disease, Clin0 MDS, Clin0 Gaucher disease, RD X-SCID; undisclosed RD thalassemias, sickle cell disease, RD autoimmune diseases

Jasper Therapeutics develops antibody therapies for stem cell transplants. The company's mission is to make safer and potentially curative therapies possible for more patients in need. Jasper Therapeutics is developing briquilimab, a unconjugated, aglycosylated, anti-c-Kit monoclonal antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, SCF. By blocking SCF from binding to c-Kit, briquilimab causes mast cells to undergo orderly cell death. Briquilimab can be used to treat chronic mast and stem cell diseases such as chronic urticaria, lower to intermediate risk myelodysplastic syndromes (MDS), and complications from stem cell transplants.

Jobs: